Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

Cited In for PubMed (Select 12610718)


Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia.

Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, Iyo M.

J Psychopharmacol. 2015 Apr;29(4):383-9. doi: 10.1177/0269881115570083. Epub 2015 Mar 3.


The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study.

Hashimoto K, Sugawara N, Ishioka M, Nakamura K, Yasui-Furukori N.

Neuropsychiatr Dis Treat. 2014 Aug 22;10:1571-6. doi: 10.2147/NDT.S68298. eCollection 2014.


The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Peuskens J, Pani L, Detraux J, De Hert M.

CNS Drugs. 2014 May;28(5):421-53. doi: 10.1007/s40263-014-0157-3. Review.


Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.

Awad G, Hassan M, Loebel A, Hsu J, Pikalov A, Rajagopalan K.

BMC Psychiatry. 2014 Feb 23;14:53. doi: 10.1186/1471-244X-14-53.


Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).

Kelly DL, Wehring HJ, Earl AK, Sullivan KM, Dickerson FB, Feldman S, McMahon RP, Buchanan RW, Warfel D, Keller WR, Fischer BA, Shim JC.

BMC Psychiatry. 2013 Aug 22;13:214. doi: 10.1186/1471-244X-13-214.


Antipsychotic-induced sexual dysfunction and its management.

Park YW, Kim Y, Lee JH.

World J Mens Health. 2012 Dec;30(3):153-9. doi: 10.5534/wjmh.2012.30.3.153. Epub 2012 Dec 27.


The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.

Ho JG, Caldwell RL, McDougle CJ, Orsagh-Yentis DK, Erickson CA, Posey DJ, Stigler KA.

J Child Adolesc Psychopharmacol. 2012 Aug;22(4):277-83. doi: 10.1089/cap.2011.0129. Epub 2012 Jul 31.


Successful use of add - on topiramate for antipsychotic - induced weight gain.

Shivakumar V, Jayaram N, Rao NP, Venkatasubramanian G.

Indian J Psychol Med. 2012 Jan;34(1):85-6. doi: 10.4103/0253-7176.96168.


Aripiprazole: the evidence of its therapeutic impact in schizophrenia.

Winlow W, Profit L, Chrisp P.

Core Evid. 2006;1(4):251-64. Epub 2006 Jun 30.


Antipsychotic medication for early episode schizophrenia.

Bola J, Kao D, Soydan H.

Cochrane Database Syst Rev. 2011 Jun 15;(6):CD006374. doi: 10.1002/14651858.CD006374.pub2. Review.


Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia.

Barak Y, Aizenberg D.

J Obes. 2011;2011. pii: 898013. doi: 10.1155/2011/898013. Epub 2010 Aug 25.


Aripiprazole in autism spectrum disorders and fragile X syndrome.

Erickson CA, Stigler KA, Posey DJ, McDougle CJ.

Neurotherapeutics. 2010 Jul;7(3):258-63. doi: 10.1016/j.nurt.2010.04.001. Review.


Management of antipsychotic-related weight gain.

Maayan L, Correll CU.

Expert Rev Neurother. 2010 Jul;10(7):1175-200. doi: 10.1586/ern.10.85. Review.


Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole.

Kohen I, Lester PE, Lam S.

Neuropsychiatr Dis Treat. 2010 Mar 24;6:47-58.


Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study.

Lyon GJ, Samar S, Jummani R, Hirsch S, Spirgel A, Goldman R, Coffey BJ.

J Child Adolesc Psychopharmacol. 2009 Dec;19(6):623-33. doi: 10.1089/cap.2009.0035.


Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC.

J Clin Psychopharmacol. 2009 Apr;29(2):165-9. doi: 10.1097/JCP.0b013e31819a8dbe.


Commentary on strategies for switching antipsychotics.

Davis JM, Leucht S.

BMC Med. 2008 Jun 30;6:18. doi: 10.1186/1741-7015-6-18.


Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features.

Rabinowitz J, Levine SZ, Barkai O, Davidov O.

Schizophr Bull. 2009 Jul;35(4):775-88. doi: 10.1093/schbul/sbn005. Epub 2008 Feb 26.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk